Hormonal
Excessive lipolysis from visceral adipose tissue drives lipotoxicity and insulin resistance by flooding the liver with free fatty acids, leading to ectopic fat accumulation and metabolic dysfunction.
Focus on improving insulin sensitivity rather than just cutting dietary fat. Visceral fat is metabolically active and releases fatty acids that clog up your liver and muscles, causing insulin resistance. Reducing visceral fat through exercise and metabolic health improvements can lower this harmful fatty acid overflow.
Excessive accumulation of lipids can lead to lipotoxicity, cell dysfunction and alteration in metabolic pathways... The causes for lipotoxicity are not only a high fat diet but also excessive lipolysis... In presence of either high fat and/or carbohydrate intake, lipogenesis is stimulated and excess fat is stored as triglycerides... During fasting excess plasma free fatty acids (FFA), mainly released by the subcutaneous fat, accumulate in non-adipose tissues (e.g., liver, heart, pancreas and muscle) as triglycerides (TG), and can promote cell dysfunction and death
Why this rating
This is a review paper citing multiple human studies and mechanistic data, establishing a strong consensus on the link between lipolysis, FFA flux, and insulin resistance.
Source
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Chiara Saponaro et al. · Nutrients · 2015
DOI 10.3390/nu7115475
More from this paper
- Visceral adipose tissue is more lipolytically active than subcutaneous fat, releasing fatty acids directly into the portal vein to the liver, thereby driving hepatic steatosis and insulin resistance more strongly than subcutaneous fat.Good
- De novo lipogenesis (DNL) contributes significantly to hepatic triglyceride accumulation in insulin-resistant states, particularly when driven by high carbohydrate intake, and is a target for drugs like pioglitazone and liraglutide.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →